Description
The INVOKE-2 failure highlighted that current TREM2-targeting approaches may be fundamentally flawed due to delivery issues. The Expert noted this as a major druggability challenge requiring resolution.
Source: Debate session sess_SDA-2026-04-10-trem2-ad (Analysis: trem2-ad)
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:52.464712+00:00”, “resolution_summary”: “Resolved by hypothesis h-analogy-daabed82: TREM2-Modulating LNPs for Neurodegeneration: Cell-Type-Specific Immunometabolic Targeting via Microglial Modulation. Supporting evidence includes debate sess_sda-2026-04-01-001.”, “match_counts”: {“hypothesis_matches”: 5, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-analogy-daabed82”, “title”: “TREM2-Modulating LNPs for Neurodegeneration: Cell-Type-Specific Immunometabolic Targeting via Microglial Modulation”, “score”: 0.356, “reason”: “8 token overlaps; entity overlap: trem2, trem2-”, “analysis_id”: null, “target_gene”: “TREM2”, “target_pathway”: “Neuroinflammation-Immunometabolism”, “disease”: “neurodegeneration”, “composite_score”: 0.55, “confidence_score”: 0.45, “status”: “active”, “pubmed_evidence_ids”: []}, {“id”: “h-3460f820”, “title”: “TREM2-Mediated Selective Aggregate Clearance Pathway”, “score”: 0.354, “reason”: “4 token overlaps; entity overlap: trem2, trem2-”, “analysis_id”: “SDA-2026-04-01-gap-9137255b”, “target_gene”: “TREM2”, “target_pathway”: “TREM2 → SYK → PI3K/mTOR phagocytic signaling”, “disease”: “neurodegeneration”, “composite_score”: 0.584, “confidence_score”: 0.5, “status”: “proposed”, “pubmed_evidence_ids”: [“29899446”, “31398344”, “32719508”]}, {“id”: “h-var-a4ec87f152”, “title”: “TREM2-Senescence Cascade in Astrocyte-Microglia Communication Breakdown”, “score”: 0.342, “reason”: “16 token overlaps; entity overlap: trem2, trem2-”, “analysis_id”: “SDA-2026-04-03-gap-aging-mouse-brain-v3-20260402”, “target_gene”: “TREM2”, “target_pathway”: “TREM2/TYROBP senescence-mediated glial communication disruption”, “disease”: “neurodegeneration”, “composite_score”: 0.574, “confidence_score”: 0.53, “status”: “promoted”, “pubmed_evidence_ids”: [“20301376”, “24047521”, “28802038”, “30258234”, “31932797”]}, {“id”: “SDA-2026-04-02-gap-tau-prop-20260402003221-H002”, “title”: “TREM2-mediated microglial tau clearance enhancement”, “score”: 0.339, “reason”: “19 token overlaps; entity overlap: trem2, trem2-”, “analysis_id”: “SDA-2026-04-04-gap-tau-prop-20260402003221”, “target_gene”: “TREM2”, “target_pathway”: “TREM2/TYROBP microglial signaling”, “disease”: “neurodegeneration”, “composite_score”: 0.780383, “confidence_score”: 0.665, “status”: “proposed”, “pubmed_evidence_ids”: [“24990881”, “28602351”, “28802038”, “31932797”, “33516818”]}, {“id”: “h-44b1c9d415”, “title”: “TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxicity in Alzheimer’s Disease”, “score”: 0.338, “reason”: “5 token overlaps; entity overlap: trem2, trem2-”, “analysis_id”: “legacy-pre-pipeline-import-v1”, “target_gene”: “TREM2”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.827427, “confidence_score”: 0.88, “status”: “proposed”, “pubmed_evidence_ids”: [“26741508”, “28165511”, “29196612”]}], “debate_matches”: [{“id”: “sess_sda-2026-04-01-001”, “title”: “What are the most promising therapeutic strategies for targeting TREM2 in Alzheimer’s disease, given the INVOKE-2 failure?”, “score”: 0.448, “reason”: “4 token overlaps; entity overlap: invoke-2, trem2”, “analysis_id”: “sda-2026-04-01-001”, “quality_score”: 0.95, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-11-gap-debate-20260410-100405-abac24bc”, “title”: “The debate proposed biphasic TREM2 modulation but couldn’t define when to switch from inhibition to activation. The Skeptic noted AD lacks discrete temporal phases, making this critical for any temporal therapeutic strategy.\n\nSource: Debate session sess_SDA-2026-04-10-trem2-ad (Analysis: trem2-ad)”, “score”: 0.388, “reason”: “8 token overlaps; entity overlap: trem2”, “analysis_id”: “SDA-2026-04-11-gap-debate-20260410-100405-abac24bc”, “quality_score”: 0.3, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-10-trem2-ad”, “title”: “TREM2 Therapeutic Strategy Post-INVOKE-2?”, “score”: 0.387, “reason”: “2 token overlaps; entity overlap: invoke-2, trem2”, “analysis_id”: “trem2-ad”, “quality_score”: 0.95, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-06-gap-001”, “title”: “TREM2 Therapeutic Strategy Post-INVOKE-2”, “score”: 0.387, “reason”: “2 token overlaps; entity overlap: invoke-2, trem2”, “analysis_id”: “SDA-2026-04-06-gap-001”, “quality_score”: 0.93, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-11-gap-debate-20260410-100409-e0118210”, “title”: “The debate proposed temporal TREM2 modulation but couldn’t define when to switch from inhibition to activation phases. This fundamental timing question remains unresolved despite being critical for therapeutic success.\n\nSource: Debate session sess_SDA-2026-04-10-trem2-ad (Analysis: trem2-ad)”, “score”: 0.35, “reason”: “7 token overlaps; entity overlap: trem2”, “analysis_id”: “SDA-2026-04-11-gap-debate-20260410-100409-e0118210”, “quality_score”: 0.3, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}